Navigation Links
Thomas, McNerney & Partners Promotes Two Members of its Investment Team
Date:1/25/2011

STAMFORD, Conn. and MINNEAPOLIS, Jan. 25, 2011 /PRNewswire/ -- Thomas, McNerney & Partners, LLC, a health care venture capital firm that invests in life science and medical technology companies, today announced the promotions of Kathy Tune to Partner and Anya Schiess to Vice President.

"These promotions are much-deserved acknowledgements of the important contributions Kathy and Anya have made as members of the Thomas, McNerney investment team," said James Thomas of Thomas, McNerney.  "Both have clearly demonstrated their abilities to identify and assess health care investment opportunities and are ready to assume greater responsibilities within our organization."

Kathy Tune, based in the firm's Minneapolis office, joined Thomas, McNerney in 2003.  She focuses primarily on the medical device sector.  Previously, she was a health care analyst at Piper Jaffray & Co., covering companies in the medical device, medical supply, and diagnostic areas.  Earlier in her career, she was a new product development manager at Solvay, S.A. Kathy has an M.S. in Microbiology from the University of Minnesota and an M.B.A. from the University of Minnesota's Carlson School of Management, where she was a Robert and Gail Buuck Scholar.  Kathy is on the board of directors of the Mid-America Healthcare Investors Network and is active with the American Heart Association.

Anya Schiess, based in the firm's Stamford, CT office, joined Thomas, McNerney in 2008 from Medtronic, Inc., where she held several sales and marketing leadership roles in the U.S. and Europe.  Prior to Medtronic, Anya was a member of the William Jefferson Clinton Presidential Foundation HIV/AIDS initiative.  Earlier in her career, she was a consultant at McKinsey & Company.  Anya works across the firm's investment areas, with a particular focus on diagnostic investments.  She received her A.B. cum laude from Princeton University and her M.B.A. with honors from the Wharton School at the University of Pennsylvania.  

About Thomas, McNerney & Partners

Thomas, McNerney & Partners is a health care venture capital firm with approximately $600 million under management, focused on investing in life science and medical technology companies at all stages of development.  In addition to helping entrepreneurs launch companies with seed and early stage funding, the firm provides growth capital to emerging companies to advance clinical development or for product commercialization.  Thomas, McNerney & Partners also is involved in spinning out products and divisions from major medical device and pharmaceutical companies, consolidating companies through roll-up strategies and participating in structured financings for public companies, as well as recapitalizations.  The firm has offices in Connecticut, Minnesota and California. For further information, please visit www.tm-partners.com.


'/>"/>
SOURCE Thomas, McNerney & Partners, LLC
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. CardioWest™ Artificial Heart Approved For Highest Reimbursement in CMS History : Plus Up To $53,000 New Technology Add-on Payments
2. 4C Controls Announces the Appointment of Dr. Philip Hayden as Vice President, Security Assessment & Threat Analysis
3. Bruker Introduces HyperQuant™, a Unique Bench-Top NMR Reader to Quantify Hyperpolarization
4. Biotechnology & Drug Discovery Markets Push Up Demand for Lab Automation Products, According to a New Report by Global Industry Analysts
5. Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™
6. The Modern DeBakey VAD™ To Be Introduced For the First Time in the U.S. : HeartAssist 5™ Pediatric VAD Features Industry Exclusive Direct Blood Flow Measurement System
7. New Innovation Set to Revolutionise Spray Technology - Used to Protect Against the Scottish Biting Midge & Help Fight MRSA in the NHS
8. "Put Down the BBQ Ribs, We've Found You a Donor Heart," Nurse Tells Patient : Ohio Father near Death Gets Second Chance at Life with CardioWest™ temporary Total Artificial Heart
9. Riverock Technologies Helps Misukanis & Odden Eliminate Task Management Obstacles
10. Microplate Instrumentation & Supplies Market to Exceed $5.0 Billion by 2015, According to New Report by Global Industry Analysts, Inc
11. RNAi Helps Illuminate the Inner Workings of the Cell Cycle: Synthetic RNAissance™ Genes Created by DNA2.0 Enable Key Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... 23, 2016  The Biodesign Challenge (BDC), a university ... to harness living systems and biotechnology, announced its winning ... New York City . ... showcased projects at MoMA,s Celeste Bartos Theater during the ... MoMA,s senior curator of architecture and design, and ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology:
(Date:4/28/2016)... Sweden , April 28, 2016 First ... M (139.9), up 966% compared with the first quarter of 2015 ... profit totaled SEK 589.1 M (loss: 18.8) and the operating margin ... 7.12 (loss: 0.32) Cash flow from operations was SEK ... The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)... 15, 2016  A new partnership announced today ... underwriting decisions in a fraction of the time ... and high-value life insurance policies to consumers without ... With Force Diagnostics, rapid testing (A1C, Cotinine and ... (blood pressure, weight, pulse, BMI, and activity data) ...
(Date:3/31/2016)...   LegacyXChange, Inc. ... LegacyXChange is excited to release its first ... be launched online site for trading 100% guaranteed authentic ... also provide potential shareholders a sense of the value ... industry that is notorious for fraud. The video is ...
Breaking Biology News(10 mins):